Alzheimer’s Research UK starts AI-based drug hunt with ExscientiaMedical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments Share XAlzheimer’s Research UK starts AI-based drug hunt with Exscientiahttps://pharmaphorum.com/news/alzheimers-research-uk-starts-ai-based-drug-hunt-with-exscientia/
Early data back J&J and AC Immune’s Alzheimer’s jabShares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s Share XEarly data back J&J and AC Immune’s Alzheimer’s jabhttps://pharmaphorum.com/news/early-data-back-jj-and-ac-immunes-alzheimers-jab/
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a Share XCould Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/
FDA panel unimpressed with data for Alzheimer’s drug aducanumabThe FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors Share XFDA panel unimpressed with data for Alzheimer’s drug aducanumabhttps://pharmaphorum.com/news/fda-sceptical-on-biogen-eisai-data-for-alzheimers-drug-aducanumab/
Trials and tribulations in Biogen’s Alzheimer’s drug reviewsRegulatory reviews of Biogen’s Alzheimer’s drug aducanumab are now ongoing on both sides of the Atlantic, but debate Share XTrials and tribulations in Biogen’s Alzheimer’s drug reviewshttps://pharmaphorum.com/news/trials-and-tribulations-in-biogens-alzheimers-drug-reviews/
AC Immune poleaxed on Alzheimer’s study failShares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a Share XAC Immune poleaxed on Alzheimer’s study failhttps://pharmaphorum.com/news/ac-immune-poleaxed-on-alzheimers-study-fail/
Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120mRoche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a Share XRoche doubles down on tau for Alzheimer’s, licensing UCB drug for $120mhttps://pharmaphorum.com/news/roche-doubles-down-on-tau-for-alzheimers-licensing-ucb-drug-for-120m/
Deep Dive: Market Access – Breaking BarriersIn this issue of Deep Dive we look at the changing landscape for pharma market access and start Share XDeep Dive: Market Access – Breaking Barriershttps://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access/
Alkermes bolts on Rodin Therapeutics to bulk up thin pipelineAlkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative Share XAlkermes bolts on Rodin Therapeutics to bulk up thin pipelinehttps://pharmaphorum.com/news/alkermes-bolts-on-rodin-therapeutics-to-bulk-up-thin-pipeline/
